Edoardo Aromataris

University of Adelaide
Country flagAustralia

Research Interests

Explore related searches

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (18)

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Objective: The objective of this systematic review is to investigate oncological and functional outcomes following primary transoral surgery compared with non-surgical management in patients with small-volume (T1-2, N0-2) oropharyngeal cancer. Introduction: The incidence of oropharyngeal cancer is rising. Transoral surgery was introduced to provide a minimally invasive treatment option for patients with small-volume oropharyngeal cancer and to avoid the morbidity that results from open surgery and the potential acute and late toxicities of chemoradiotherapy. Inclusion criteria: The review will include all studies on adult patients with small-volume oropharyngeal cancer managed by transoral surgery or non-surgical management with radiotherapy and/or chemotherapy. All patients must have undergone treatment with curative intent. Participants who underwent palliative treatment will be excluded. Methods: This review will follow the JBI methodology for systematic reviews of effectiveness. Eligible study designs will include randomized controlled trials, quasi-experimental studies, and prospective or retrospective cohort studies. Databases to be searched will include PubMed, Embase, CINAHL, Cochrane CENTRAL, and multiple trial registries from 1972. Titles and abstracts will be reviewed, and full-text articles will be retrieved if they meet the inclusion criteria. All eligible studies will be critically appraised by 2 independent reviewers using the appropriate JBI tools for experimental and observational designs. Where possible, outcome data from studies will be pooled with statistical meta-analysis to compare both oncological and functional outcomes between the two groups. All time to event to data will be converted to a common metric for oncological outcomes. The Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach will be followed to assess the certainty of findings. Review registration: PROSPERO CRD4202235209

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Collaborators (15)

David Graeme Hancock

University in Western Australia

AUSTRALIA
View details

Jonathan Riddle

Professor

Texas Christian University

UNITED STATES
View details

Yuri Jadotte

Assistant Professor and Assistant Program Director of Preventive Medicine Residency

Stony Brook Medicine

UNITED STATES
View details

Anna Mae Scott

Bond University

AUSTRALIA
View details

Craig Lockwood

-

AUSTRALIA
View details

Catrin Evans

Professor

University of Nottingham

UNITED KINGDOM
View details

Stephen Harfield

University of Queensland

AUSTRALIA
View details

Zachary Munn

University of Adelaide

AUSTRALIA
View details

Olinda Santin

The Queen's University Belfast

UNITED KINGDOM
View details

Gillian Carter

Lecturer in Chronic Illness

The Queen's University Belfast

UNITED KINGDOM
View details

Romy Menghao Jia

Lecturer

University of Adelaide

AUSTRALIA
View details

Amanda Ross-White

-

CANADA
View details

Hanan Khalil

Associate Professor

La Trobe University

AUSTRALIA
View details

Daphne Stannard

Tenured Associate Professor Emerita

San Francisco State University

UNITED STATES
View details

Miloslav Klugar

Masaryk University

CZECH REPUBLIC
View details
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.